Puma Biotechnology reported $202.86M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 96.05B 409M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Daiichi Sankyo JPY 4.26T 144.08B Sep/2026
Exelixis USD 2.51B 19.26M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Glaxosmithkline GBP 71.7B 8.83B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
MacroGenics USD 318.68M 26.72M Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Takeda JPY 15.27T 391.77B Sep/2026
TG Therapeutics USD 1.59B 47.38M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026